Biological E to use Dynavax’s adjuvant in Corbevax

Biological E (BE) on Tuesday said it will use U.S. biopharmaceutical firm Dynavax Technologies Corporation’s CpG 1018 advanced adjuvant in its sub unit COVID-19 vaccine candidate Corbevax.The firms ha

Biological E (BE) on Tuesday said it will use U.S. biopharmaceutical firm Dynavax Technologies Corporation’s CpG 1018 advanced adjuvant in its sub unit COVID-19 vaccine candidate Corbevax. The firms have entered into a commercial supply agreement that extends through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax, said Biological E, which expects to unveil Corbevax later this year subject to regulatory approvals. Last month, while stating it had finalised arrangements with Biological E to reserve 30 crore doses of the vaccine, the Union Ministry of Health had said the vaccine was undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2.